Apr 21, 2026 Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 Learn More
Apr 14, 2026 Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) Learn More
Mar 4, 2026 Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates Learn More
Feb 25, 2026 Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 Learn More